ABP 980 — Competitive Intelligence Brief

ABP 980 (ABP 980) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibody-drug conjugate (ADC). Area: Oncology.

phase 3 Antibody-drug conjugate (ADC) HER2 Oncology Small molecule

Target snapshot

ABP 980 (ABP 980) — Amgen. ABP 980 is a HER2-targeting antibody-drug conjugate that delivers cytotoxic payload to HER2-expressing cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABP 980 TARGET	ABP 980	Amgen	phase 3	Antibody-drug conjugate (ADC)	HER2
NERATINIB	NERATINIB		marketed		EGFR, HER2, HER4	2017-01-01
Herceptin	Trastuzumab-Qyyp	Roche	marketed	HER2/neu receptor antagonist monoclonal antibody	HER2 (c-erbB2) proto-oncogene transmembrane receptor protein	1998-01-01
Herceptin	trastuzumab	Roche	marketed	Antibody-drug conjugate (ADC)	HER2 receptor, subdomain IV	1998-01-01
BIZENGRI	ZENOCUTUZUMAB-ZBCO	MERUS N.V.	marketed		HER2, HER3
Disitamab vedotin	disitamab-vedotin	Pfizer	marketed	antibody-drug conjugate	human epidermal growth factor receptor 2 (HER2)
SEVABERTINIB	SEVABERTINIB		marketed		HER2, EGFR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibody-drug conjugate (ADC) class)

1. Pfizer · 3 drugs in this class
2. Jiaxing AnDiCon Biotech Co.,Ltd · 2 drugs in this class
3. AstraZeneca · 1 drug in this class
4. BioAtla, Inc. · 1 drug in this class
5. Byondis B.V. · 1 drug in this class
6. Charite University, Berlin, Germany · 1 drug in this class
7. Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in this class
8. Medstar Health Research Institute · 1 drug in this class
9. OBI Pharma, Inc · 1 drug in this class
10. On Target Laboratories, LLC · 1 drug in this class